Mineralys Therapeutics, Inc. Common Stock (MLYS NASDAQ) stock market data APIs
$26.9326
-0.34(-1.3%)
as of June 29, 2026
Try our APIs with
free plan!
Mineralys Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Prev. Close
26.9326
Open
26.591
High
26.9458
Low
26.2737
52 wk Range
12.59-47.65
Market Cap
2 370 M
Shares Outstanding
88 158 K
EPS
-0.47
Beta
0.565
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Mineralys Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mineralys Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Mineralys Therapeutics, Inc. Common Stock Fundamental Data
Mineralys Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -171 447 008
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Mineralys Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-18
- EPS/Forecast: -0.81
Get Mineralys Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mineralys Therapeutics, Inc. Common Stock News
New
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
Key Points The Chief Medical Officer of Mineralys Therapeutics reported selling 14,474 Common Stock shares across multiple transactions on June 15 and June 17, 2026, for a total value of approximatel...
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics (NASDAQ:MLYS), reported the direct sale of 14,474 shares of Common Stock for a total transaction value of approximately $350,000, a...
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best young stocks to invest in according to hedge funds. On June 3, Mineralys Therapeutics announced the pricing of an underwritten public offer...
Mineralys Reports Lorundrostat Reduced Heart Failure Risk Biomarkers In Hypertension Trials
(RTTNews) - Mineralys Therapeutics, Inc. (MLYS), reported positive post hoc data from Phase 3 Launch-HTN and Phase 2b Advance-HTN trials on the effect of Lorundrostat on heart failure risk biomarkers....
Get Mineralys Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
